Now: GlaxoSmithKline sold off its gene therapies—straight up, outright cures for diseases—to startup Orchard Therapeutics for a 20 percent stake in the firm.The problem: Genetic treatments cure people, so firms will run out of patients. Plus many of the treatable diseases are rare, so there aren’t many patients anyway.
What now? “Society has to find a balance between the extraordinary value we are bringing and a sustainable business model,” says Mark Rothera, CEO of Orchard.

from MIT’s daily heads-up in tech
The Download from MIT Tech Review <newsletters